Erik Anders Kronström
Geschäftsführer bei INFANT BACTERIAL THERAPEUTICS AB
Vermögen: 89 953 $ am 30.04.2024
Profil
Erik Anders Kronström is currently the Chief Operating Officer at Infant Bacterial Therapeutics AB since 2018.
Previously, he worked as the Chief Executive Officer at Biosergen AS.
He holds an MBA from Warwick Business School and a graduate degree from the Royal Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.05.2023 | 11 194 ( 0,09% ) | 89 953 $ | 30.04.2024 |
Aktive Positionen von Erik Anders Kronström
| Unternehmen | Position | Beginn |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Geschäftsführer | 01.01.2018 |
Ehemalige bekannte Positionen von Erik Anders Kronström
| Unternehmen | Position | Ende |
|---|---|---|
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Vorstandsvorsitzender | - |
Ausbildung von Erik Anders Kronström
| Royal Institute of Technology | Graduate Degree |
| Warwick Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
